We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Non-Invasive Imaging Detects Cancer at Molecular Level

By LabMedica International staff writers
Posted on 20 Aug 2019
Print article
Image: Scientists combined multiphoton microscopy with automated image and statistical analysis algorithms to distinguish between healthy and diseased tissue. In this image, collected in a completely label-free, noninvasive manner, collagen is colored green while ovarian metastatic cell clusters are presented in red (Photo courtesy of Tufts University).
Image: Scientists combined multiphoton microscopy with automated image and statistical analysis algorithms to distinguish between healthy and diseased tissue. In this image, collected in a completely label-free, noninvasive manner, collagen is colored green while ovarian metastatic cell clusters are presented in red (Photo courtesy of Tufts University).
For cancer patients the presence of metastases dictates the staging assessment, which in turn defines the appropriate treatment path selected. For gynecological malignancies, like ovarian carcinoma, it is of immense importance to differentiate between localized and metastatic disease status as that drastically affects management.

For in situ, real time diagnosis, novel imaging modalities that offer metabolic and structural information at the cellular and subcellular level can be of great help, especially since these modalities are being progressively incorporated in probes and micro-endoscopes that allow intra-vital access to organs that lie deeper in the body.

Biomedical scientists at Tufts University (Medford, MA, USA) and their colleagues collected samples from eight patients who underwent open laparotomy as part of routine medical care. Post completion of all intra-abdominal procedures of the operation, eight biopsies of healthy parietal peritoneum and if present of four peritoneal metastases were collected from each patient. All lesions were evaluated by a pathologist using standard hematoxylin and eosin histology.

The tissues were imaged employing a multiphoton laser scanning microscope to generate intrinsic fluorescence and second harmonic generation (SHG) images at 755 nm and 900 nm excitation respectively with signal emission collected at 460 ± 20 and 525 ± 25 nm. Laser light was focused on the sample using a 25x objective (0.9 NA / water-immersion), and neutral density filters were employed to achieve a power of 25–35 mW. At least two to three random fields per tissue were evaluated, reaching a total of 30 and 11 images for the healthy and metastatic biopsy tissue groups, respectively (512 × 512 pixels; 600-micron field of view; resolution of 1.17 microns per pixel). Imaging was focused within a depth of ∼20-100 microns from the mesothelial surface of the tissues.

The team found that healthy tissues displayed large variations in contrast and correlation features as a function of distance, corresponding to repetitive, increased local intensity fluctuations. Metastatic tissue images exhibited decreased contrast and correlation related values, representing more uniform intensity patterns and smaller fibers, indicating the destruction of the healthy stroma by the cancerous infiltration. Analyzing 41 images acquired from the biopsies, the technique correctly classified 40 out of 41 images (an accuracy of 97.5%). A total of 11 samples were correctly classified as metastatic (100% sensitivity) and 29 of 30 were correctly classified as healthy (96.6% specificity).

Dimitra Pouli, MD, PhD, a Pathology Resident and co-author of the study, said, “The method utilized in this work identifies in a completely label-free manner cellular and tissue features at the microscopic level, essentially acting like a biopsy without a knife,” The study was published in the August 2019 issue of the journal Biomedical Optics Express.

Related Links:
Tufts University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.